منابع مشابه
Non-myeloablative transplants for malignant disease.
This article discusses changes in the way hematopoietic stem cell allotransplants may be carried out in the future to treat patients with malignant hematological diseases. Specifically, the focus has shifted away from attempts at eradicating underlying diseases through toxic high-dose chemoradiation therapy towards using the stem cell donor's immune cells for that purpose (allogeneic graft-vers...
متن کاملNon-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma.
OBJECTIVE To present an institution's 2-year experience of non-myeloablative allogeneic stem cell transplantation among Chinese patients. DESIGN Retrospective study. SETTING Bone marrow transplantation unit at a university hospital, Hong Kong. PATIENTS Ten patients with multiple myeloma who received non-myeloablative allogeneic stem cell transplantation between March 2000 and October 2002...
متن کاملPrevalence of chimerism after non-myeloablative hematopoietic stem cell transplantation.
CONTEXT AND OBJECTIVE Non-myeloablative hematopoietic stem cell transplantation (NMA-HSCT) is performed in onco-hematological patients who cannot tolerate ablative conditioning because of older age or comorbidities. This approach does not completely eliminate host cells and initially results in mixed chimerism. Long-term persistence of mixed chimerism results in graft rejection and relapse. Inv...
متن کاملA Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a curative treatment option for both malignant and some benign hematological diseases. During the last decade, many of the newer high-dose regimens in different intensity have been developed specifically for patients with hematologic malignancies and solid tumors. Today there are three main approaches used prior to allogeneic tra...
متن کاملPeripheral blood stem cell transplants.
Autologous peripheral blood stem cell transplantation High dose myeloablative treatment followed by autologous haemopoietic stem cell rescue is increasingly used in the treatment of haematological malignancies and solid tumours with the aim of achieving a dose–response eVect. Apart from the risk of disease relapse, the major drawback of this approach is the risk of procedure related toxicity re...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 2000
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2000.02405.x